NOTE: Patients with documented bone marrow involvement by lymphoma are not required to meet the above hematologic parameters, but must have a platelet count of at least ,/mcL and neutrophil count of at least ,/mcL
Absolute neutrophil count >= ,/mcL (unless documented bone marrow involvement with lymphoma)
Platelet count >= ,/uL (unless documented bone marrow involvement with lymphoma)
Platelet count >= ,/?L (unless documented bone marrow involvement with lymphoma)
Absolute neutrophil count (ANC) >=  unless due to direct bone marrow involvement of disease
Absolute neutrophil count (ANC) ? , cells/mm (. x /L) unless secondary to extensive bone marrow involvement by lymphoma (ie, ? %) as demonstrated by unilateral bone marrow core biopsy performed during Screening or within  months prior to signing the ICF. In the case of documented extensive bone marrow involvement an ANC ? , cells/mm (. x /L) is required.
Platelet count ? ,/mm ( x /L) unless secondary to extensive bone marrow involvement by lymphoma (ie, ? %) as demonstrated by unilateral bone marrow core biopsy performed during Screening or within  months prior to signing the ICF. In the case of documented extensive bone marrow involvement, a platelet count of ? ,/ mm ( x /L) is required.
Absolute neutrophil count (ANC) >= ,/mm^ \r\n* Exception: unless documented bone marrow involvement by lymphoma
Platelet count ? ,/uL\r\n* The above criteria do not have to be met if the patient has bone marrow involvement of tumor
ANC < . x ^/L or platelet count <  x ^/L unless due to disease involvement in the bone marrow.
Platelet count >= ,/mm^ in the absence of bone marrow involvement; patients with bone marrow involvement only require a platelet count of >= ,/mm^
Platelet count >= ,/uL unless due to heavily infiltrated bone marrow (> % CLL cell infiltrate)
Absolute neutrophil count >  /uL unless due to heavily infiltrated bone marrow (> % CLL cell infiltrate)
Absolute neutrophil count ? /mm^, unless due to disease involvement in the bone marrow
Within  days prior to administration of study treatment: Absolute neutrophil count (ANC) >= . x ^/L (unless due to bone marrow infiltration by tumor, in which case ANC > ,/mm^ is allowed).
Hematologic: ANC . x /L, Hgb ? . g/dL and platelet count  x /L (platelet count >  x /L if documented evidence of bone marrow involvement).
Absolute neutrophil count: >= ,/mm^, unless decreased due to bone marrow involvement with lymphoma
Absolute neutrophil count (ANC) >= /mm^, unless due to disease involvement in the bone marrow
Absolute neutrophil count (ANC) < /mm^ unless lymphoma, KSHV-MCD, or KICS-related
Platelet count >= ,/ul (unless documented bone marrow involvement with lymphoma)
Absolute neutrophil count (ANC) > /mm^ unless deemed related to lymphoma involvement in the bone marrow and felt potentially reversible by the treating physician
Platelet count >=   ^/L (>=   ^/L if myeloma involvement in the bone marrow is > %)
Absolute neutrophil count (ANC) >= . x ^/L; ANC < . x ^/L if cytopenia is due to extensive bone marrow involvement of disease as determined by the treating physician
Platelet count >=  x ^/L (>=  x ^/L if lymphoma involvement in the pre-treatment bone marrow is found) within  days prior to starting therapy
Absolute neutrophil count (ANC) > , unless due to direct bone marrow involvement of disease
Platelet count >= . x ^/L or =< . x ^/L but >= . x ^/L due to > % marrow involvement\r\n* Patients who entered the trial prior to June ,  were restricted to > % marrow involvement
Absolute neutrophil count of less than  cells/ul unless low neutrophil count is thought to be due to malignancy in the bone marrow and malignancy is documented in the bone marrow
Platelet count less than ,/uL unless low platelet count is thought to be due to malignancy in the bone marrow and malignancy is documented in the bone marrow
Patients must have evidence of adequate bone marrow reserve as shown by absolute neutrophil count (ANC) of at least ,/mm^; however, if the cytopenias are due to extensive bone marrow involvement by CLL, patients may be included in the study
To be performed within  days prior to day  of protocol therapy: absolute neutrophil count (ANC) >= ,/mm^\r\n* NOTE: Growth factor is not permitted within  days of ANC assessment unless cytopenia is secondary to disease involvement\r\n* Exception: Unless documented bone marrow involvement by lymphoma
Absolute neutrophil count (ANC) > , unless due to direct bone marrow involvement of disease
Absolute neutrophil count (ANC) >= /mm^, unless secondary to bone marrow involvement; obtained =<  days prior to registration
Platelet count ?   /L  (?   /L if WM involvement in the bone marrow is >\n             %) within  days prior to randomization
ANC ? . x ^/L or platelet count ?  x ^/L unless due to disease involvement in the bone marrow.
Patients known to have bone marrow involvement with neuroblastoma are eligible provided that minimum ANC and platelet count criteria are met but are not evaluable for hematological toxicity
Platelet count >= ,/L unless due to heavily infiltrated bone marrow (> % CLL cell infiltrate); AND
Absolute neutrophil count > /uL unless due to heavily infiltrated bone marrow (> % CLL cell infiltrate)
Absolute neutrophil count >= ,/mcl unless in the opinion of the treating physician, neutropenia is due to splenomegaly or bone marrow involvement
Absolute neutrophil count (ANC) >  cells/mm^, unless cytopenias due to non-Hodgkin lymphoma (NHL) (i.e., bone marrow involvement or splenomegaly)
Absolute neutrophil count (ANC) >=  independent of growth factor support; (patients who have cytopenias due to significant bone marrow infiltration do not have to meet hematologic eligibility criteria; significant bone marrow infiltration is defined as > % involvement by CLL)
PHASE II: If the patient had significant bone marrow involvement (bone marrow [BM] plasma cells >= %), a platelet count >= , mm^ and absolute neutrophil count (ANC) >= /mm^ is required
Absolute neutrophil count (ANC) < . x /L or platelet count <  x /L unless due to disease involvement in the bone marrow.
ANC < . x /L or platelet count <  x /L unless there is bone marrow involvement.
Platelet count >= ,/mm^ (unless due to bone marrow infiltration by tumor in which case >= ,/ml are allowed)
Lab criteria of absolute neutrophil count (ANC) >/=  cells/mm, platelets >/= , cells/mm if baseline bone marrow negative for TCL involvement and platelets >/= , cells/mm if baseline bone marrow positive for TCL involvement, bilirubin </=  x upper limits of normal (ULN) (Gilbert's </=  x ULN), creatinine </= . x ULN, and ALT and AST </=  x ULN.
Adequate baseline platelet and neutrophil levels must be present, unless there is clear evidence of extensive bone marrow involvement with tumor infiltration; extensive bone marrow involvement is defined as:\r\n* Bone marrow lymphocytes >= %
Minimum absolute neutrophil count of , cells/ul and minimum platelet count (without transfusion) of ,/mm^; values below these levels may be accepted at the discretion of the PI, if thought to be due to bone marrow involvement by malignancy
Absolute neutrophil count (ANC) >  unless impairment due to organ involvement by lymphoma
Lymphoma participants without bone marrow involvement must have absolute neutrophil count (ANC) >= ,/mm^; Note: these criteria are waived for participants with leukemia or lymphoma participants with bone marrow involvement
Lymphoma participants without bone marrow involvement must have platelet count >= ,/mm^ (without transfusion support); Note: these criteria are waived for participants with leukemia or lymphoma participants with bone marrow involvement
Absolute neutrophil count (ANC) >= . unless cytopenias are related to bone marrow involvement with disease
Marrow involvement less than % at transplantation, no limitation on blood counts (low platelet count allowed)
Absolute neutrophil count (ANC) >= . x ^/L, unless due to bone marrow involvement with lymphoma
Lymphoma participants without bone marrow involvement must have: \r\n* Absolute neutrophil count (ANC) >= ,/L, and\r\n* Platelet count > ,/mm^ (without transfusion support)\r\n** Note: these criteria are waived for participants with leukemia or lymphoma participants with bone marrow involvement
Absolute neutrophil count >= ,/mcL (unless due to lymphoma involvement of the bone marrow)
Absolute neutrophil count (ANC) >= /uL, unless due to bone marrow involvement by lymphoma
If patient has extensive bone marrow involvement, minimum ANC and platelet levels are not required.
Absolute neutrophil count ?,/L (unless due to documented leukemic involvement of the bone marrow at the time of study entry)
Platelet count ?   ^/L (?   ^/L if myeloma involvement in the bone marrow is > %) within  days prior to randomization
Absolute neutrophil count (ANC) > /mm^ unless deemed likely related to lymphoma involvement in the bone marrow where the minimum ANC allowable will be /mm^
Platelets > ,/mm^ unless deemed likely related to lymphoma involvement in the bone marrow where minimum allowable platelet count will be ,/mm^
Absolute neutrophil count (ANC) >= ,/?L unless due to marrow involvement by lymphoma
Bone marrow reserve: absolute neutrophil count (ANC) >=/microliter (?L), platelet count >=,/?L (>=,/?L for participants with bone marrow involvement), and hemoglobin >= gram per deciliter (g/dL).
Adequate bone marrow reserve: absolute neutrophil count (ANC) greater than or equal to (>=)  per micro litre (/mcL), platelet count >=,/mcL (>=,/mcL for participants with bone marrow involvement), and hemoglobin >= gram per deciliter (g/dL) (red blood cell [RBC] and platelet transfusion allowed >= days before assessment).
Platelets >=  x ^/L (or platelet count >=  x ^ cells/L in patients with lymphoma or CLL if bone marrow disease involvement is documented)
Absolute neutrophil count >=  cells/mm^ (. x ^/L), unless they have significant bone marrow involvement of their malignancy confirmed on biopsy, completed within  weeks prior to start of protocol therapy; growth factor allowed to achieve
Adequate bone marrow reserve: absolute neutrophil count (ANC) greater than or equal to (>=)  per cubic millimeter (/mm^), platelet count >=,/ mm^ (>=, per micro liter (/mcL) for participants with bone marrow involvement), and hemoglobin >= gram per deciliter (g/dL) (red blood cell [RBC] transfusion allowed >= days before assessment).
Absolute neutrophil count >=  /uL (absolute neutrophile count [ANC] values in accordance with ongoing ibrutinib studies for patients with CLL), unless cytopenias are due to bone marrow highly infiltrated with CLL cells, e.g. > %
